How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,345 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation

or chemotherapy [ Time Frame: week 1-9 ] Registered Dietitian assessed respect of the preview protocol treatment each week (radiotherapy and chemotherapy) if not respected: diarrhea is it involved. For patients that received chemotherapy, a weekly blood profile was obtained and study pills were discontinued if neutrophil count became ≤1.5 X 10(9)/L. Secondary objective were to assess whether intake of Bifilact® decreased or delayed the consumption of anti-diarrheal medication [ Time Frame: day 1-60 ] Patients (...) were asked to note, each day during the treatment,in a daily logbook intake of anti-diarrheal medication, laxatives, and antibiotics. The Registered Dietitian assessed symptoms noted with the patient each week.The duration of daily logbook was 4-9 weeks depending of the total dose of external radiotherapy Secondary objectives were to assess whether intake of Bifilact® reduced abdominal pain [ Time Frame: day 1-60 ] Abdominal pain was evaluated according to the NCI scale version 3.0: Grade 1 = mild

2013 Clinical Trials

122. Nutritional Management of Children With Chronic Diarrhea

Summary: The study objective is to assess the growth, tolerance and efficacy of a complete amino acid-based medical food in children with chronic diarrhea. Condition or disease Intervention/treatment Phase Growth and Tolerance Infant Study Other: Experimental Infant Formula Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 19 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary (...) Nutritional Management of Children With Chronic Diarrhea Nutritional Management of Children With Chronic Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Nutritional Management of Children

2013 Clinical Trials

123. Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)

Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01855711

2013 Clinical Trials

124. Acute Diarrhea

, Diarrhea , Acute Infectious Diarrhea , Infectious Diarrhea , Bacterial Diarrhea From Related Chapters II. Definition Inflammation of the gastrointestinal tract ( e and ) Typical presentation is followed by Diarrhea Most typically secondary to Can also be caused by with ingestion of preformed toxin Diarrhea Frequent liquid stools Adults: >200 g/day of stool (at least 3 s daily) Children: >20 g/kg/day of stool Timing Acute Diarrhea: Duration <2 weeks : Duration >4 weeks III. Epidemiology Foodbourne (...) es (30-40% of episodes) (90% of non- l diarhea) and s (20-30% of episodes) Inflammatory Diarrhea from and s (most common ) Shiga-toxin producing (e.g. :H7, ) Causes 30% of infectious bloody Diarrhea Non-inflammatory Diarrhea from and s Bacillus cereus VII. Risk Factors See for systemic medical condition causes of Diarrhea See Recent travel to endemic area See Travel to a developing area is associated with a 25% chance of developing Diarrhea Those with Diarrhea in a developing area have an 80

2015 FP Notebook

125. Diarrhea in HIV

) These images are a random sampling from a Bing search on the term "Diarrhea in HIV." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Diarrhea About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656 interlinked topic pages divided into a tree of 31 specialty books and 728 chapters. Content (...) Diarrhea in HIV Diarrhea in HIV Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diarrhea in HIV Diarrhea in HIV Aka: Diarrhea in HIV

2015 FP Notebook

126. Antibiotic Associated Diarrhea

Diarrhea Antibiotic Associated Diarrhea Aka: Antibiotic Associated Diarrhea , Diarrhea Secondary to Antibiotic Use , Antibiotic-Associated Diarrhea From Related Chapters II. Precautions Antibiotics in the emergency department frequently cause IV antibiotics: 26% of cases Oral antibiotics: 12% of cases , and antibiotic combinations were highest risk for Reconsider whether antibiotics are indicated and if so, if IV route is needed Oral bioavailability of most antibiotics is excellent Single dose IV (...) antibiotics prior to home oral antibiotics is rarely indicated References Arora and Menchine in Herbert (2015) EM:Rap 15(1): 11 III. Causes: Bacterial Overgrowth Syndromes secondary to antibiotics oxytoca Responds to stopping antibiotics (and possibly to stopping s) IV. Prevention: Probiotics Efficacy (NNT): 13 Treating 13 patients prevents one case of Antibiotic Associated Diarrhea Live-culture yogurt reduces due to antibiotics Lactobacillus acidophilus Lactobacillus bulgaricus thermophilus Other

2015 FP Notebook

127. Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01597505 Recruitment Status : Completed First Posted : May 14, 2012 Results First Posted : February 28, 2018 Last Update Posted

2012 Clinical Trials

128. A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. Secondary Outcome Measures : Number of Clinical Failure Events up to Day 40 [ Time Frame: Up to 30 days after EOT (up to Day 40) ] The total number of clinical failure events, which included treatment failure, CDAD recurrence, death, or being lost to follow-up, occurring during each time period was determined in each arm. Adjusted (...) A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2012 Clinical Trials

129. Lactobacillus Preparation on the Incidence of Diarrhea

of probiotics till the day of 1st diarrhea. If patients are transferred to ward, this study ends in each patient. Secondary Outcome Measures : 28day-mortality [ Time Frame: 28 day ] Mortality in 28th day of ICU residence Positive results of C.difficile toxin [ Time Frame: The first onset of diarrhea during ICU residence (up to 8 weeks) ] If diarrhea (>600ml/day) occurs during ICU residence, we will perform C.difficile toxin assays to determine the cause of diarrhea. ICU-acquired pneumonia [ Time Frame (...) Lactobacillus Preparation on the Incidence of Diarrhea Lactobacillus Preparation on the Incidence of Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lactobacillus Preparation on the Incidence

2012 Clinical Trials

130. A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01736423 Recruitment Status : Completed First Posted : November 29, 2012 Last Update Posted : October 12, 2015 Sponsor

2012 Clinical Trials

131. The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

the severity of diarrhea after 1 week of treatment in patients with MTC. Secondary Outcome Measures : Functional impact of CASAD [ Time Frame: 1 week ] To explore the functional impact of CASAD and the relative impact of diarrhea in relation to other symptom issues using MDASI-THY (M.D. Anderson Symptom Inventory-Thyroid, appendix D) Effect on thyroid function tests [ Time Frame: 1 week ] To explore the effect of CASAD on thyroid function tests, thyroid hormone and calcium absorption Changes in MDASI-THY (...) The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2012 Clinical Trials

132. Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children

. Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01968408 Recruitment Status : Completed First Posted : October 24, 2013 Last Update Posted : June 18, 2015 Sponsor: Medical University of Warsaw Information provided by (Responsible (...) Party): Hanna Szajewska, Medical University of Warsaw Study Details Study Description Go to Brief Summary: AIM: To determine the efficacy of Lactobacillus reuteri DSM 17938 at a dose of 10(9) CFU for the prevention of nosocomial diarrhea. TRIAL DESIGN: Double-blind, placebo controlled RCT. INTERVENTION: L reuteri DSM 17938 in a daily dose of 10(9) CFU. PRIMARY OUTCOME: Nosocomial diarrhoea (3 or more loose or watery stools in a 24 h that will occur more than 72 h after admission). Condition

2012 Clinical Trials

133. Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea

Bowel Syndrome (IBS) Patients With Diarrhea (IBS-D) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01667627 Recruitment Status : Completed First Posted : August 17, 2012 Last Update Posted : May 24, 2018 Sponsor: Tel-Aviv Sourasky Medical Center Information provided by (Responsible Party): Tel-Aviv (...) : Roy Dekel, MD Tel Aviv Medical Center More Information Go to Layout table for additonal information Responsible Party: Tel-Aviv Sourasky Medical Center ClinicalTrials.gov Identifier: Other Study ID Numbers: TASMC-11-RD-0491-CTIL First Posted: August 17, 2012 Last Update Posted: May 24, 2018 Last Verified: May 2018 Keywords provided by Tel-Aviv Sourasky Medical Center: IBS Probiotic hs-CRP Cholinergic status Micro-inflammation Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea

2012 Clinical Trials

134. Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

by C. difficile toxin assay. Wald 95% Confidence Intervals (CI) are presented. Secondary Outcome Measures : Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 60 Days Post-treatment. [ Time Frame: Up to 60 days post-treatment ] CDAD is defined as follows: Diarrhea: (change in bowel habits with >3 unformed bowel movements in a 24 hour period) and the presence of either toxin A and/or B (or their respective genes, tcdA and/or tcdB) of C. difficile in the stool (...) Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2012 Clinical Trials

135. Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

to Prevent ETEC Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01644565 Recruitment Status : Unknown Verified October 2015 by U.S. Army Medical Research and Materiel Command. Recruitment status was: Active, not recruiting First Posted : July 19, 2012 Last Update Posted : November 2, 2015 Sponsor (...) Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety Study of Chimeric Vaccine

2012 Clinical Trials

136. Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy

/severe (grade 2-4) diarrhea graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. II. Functional Assessment of Chronic Illness Therapy - Diarrhea (FACIT-D) Trial Outcome Index. SECONDARY OBJECTIVES: I. To evaluate the effects of probiotic supplementation on dose delays or reductions due to gastrointestinal (GI) toxicity. II. To evaluate the effects of probiotic supplementation on anti-diarrheal medication use. III. To evaluate the effects of probiotic supplementation (...) and conventional cytotoxic chemotherapy will be analyzed both combined and separately. FACIT-D Trial Outcome Index (TOI) [ Time Frame: Up to 4 weeks post treatment ] The FACIT-D TOI has a range of scores from 0-100 which are a combination of physical well being, functional well being, and diarrhea subscale. The data for patients on tyrosine kinase inhibitors and conventional cytotoxic chemotherapy will be analyzed both combined and separately. Secondary Outcome Measures : Dose delays or reductions due to GI

2012 Clinical Trials

137. Diarrhea and Oral Polio Vaccine Immunity

for poliovirus type 1 or 3 Seroconversion: proportion of children who change from seronegative to seropositive to types 1 or 3, four weeks after receipt of bOPV. Boost (increase in titer): seropositives at baseline who increase at least 4-fold in antibody titer four weeks after receipt of bOPV. Secondary Outcome Measures : Frequencies of enteric infections isolated in stool among infants with diarrhea vs. infants without diarrhea [ Time Frame: Date of enrollment ] One stool sample will be collected from each (...) Diarrhea and Oral Polio Vaccine Immunity Diarrhea and Bivalent Oral Polio Vaccine Immunity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Diarrhea and Bivalent Oral Polio Vaccine Immunity The safety

2012 Clinical Trials

138. Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

(mean) Secondary Outcome Measures : Evaluate the Clinical Outcome by Assessment of Clinical Response. [ Time Frame: Day 10 ] Positive clinical response defined as resolution of diarrhea Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. [ Time Frame: 28 days post-treatment ] Positive clinical response without recurrence through the follow-up period Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important (...) Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2012 Clinical Trials

139. Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants

Centro Pediatrico Albina Ptino More Information Go to Layout table for additonal information Responsible Party: Giuseppe Grandy, Medical Chief of Nutrition Center, Centro Pediatrico Albina de Patino ClinicalTrials.gov Identifier: Other Study ID Numbers: protzinc2012 First Posted: April 5, 2012 Last Update Posted: May 7, 2013 Last Verified: May 2013 Keywords provided by Giuseppe Grandy, Centro Pediatrico Albina de Patino: Acute Diarrhea Zinc Children Additional relevant MeSH terms: Layout table (...) Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Use

2012 Clinical Trials

140. Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea

days from Day 1 chemotherapy Placebo Comparator: Placebo Drug: Placebo 24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy Outcome Measures Go to Primary Outcome Measures : Number of Patients experiencing Diarrhea [ Time Frame: Day 1 to Day 14 ] Severity of Diarrhea will be classified according to the NCI-CTCAE. Secondary Outcome Measures : Safety and tolerability of the administered repeated doses of elsiglutide (ZP1846) will be evaluated [ Time Frame: Day 1 to Day 32 (...) Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2012 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>